CSRC Annual Meeting; Pediatric CV Safety Think Tank
Development of T2DM Drugs & Cardiovascular Safety Assessments
Call for abstracts deadline: September 8, 2010
Development of T2DM Drugs and Cardiac Safety Assessments
Cardiovascular Safety and Development of Type 2 Diabetes Mellitus Medications: Current State of the Art and Opportunities to Advance the Science.
TransRAdial Education Training and Therapy Initiative Think Tank Meeting; Review of CSRC Document “Use of Cardiac Troponin in Clinical Drug Development”
DIA/FDA/Heart Rhythm Society’s CV Safety in Drug Development
Co-sponsored by the DIA, FDA, and Heart Rhythm Society; 11-13 April 2010, 9:00am to 5:00pm daily, Sheraton National Hotel, Arlington, Virginia
Safety Evaluation of Atrial Fibrillation Ablation Using a Collaborative Pan-Stakeholder Critical Path Registry Model: CSRC Thinktank; CBI’s 4th Annual Cardiac Safety Assessment Summit
The Latest Approaches in the Evaluation of Drugs that Affect Heart Rate, Blood Pressure, QT Prolongation and Other CV Safety Related Issues.
An Educational Collaboration between the Cardiac Safety Research Consortium (CSRC), the Duke Clinical Research Institute (DCRI), the American College of Cardiology (ACC), the Heart Rhythm Society (HRS), AdvaMed, and the United States FDA.